Cargando…

In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928

Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fei, Yang, Na, Wang, Xiumin, Mao, Ruoyu, Hao, Ya, Li, Zhanzhan, Wang, Xiao, Teng, Da, Fan, Huan, Wang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399382/
https://www.ncbi.nlm.nih.gov/pubmed/30863725
http://dx.doi.org/10.3389/fcimb.2019.00048
_version_ 1783399750031114240
author Zhao, Fei
Yang, Na
Wang, Xiumin
Mao, Ruoyu
Hao, Ya
Li, Zhanzhan
Wang, Xiao
Teng, Da
Fan, Huan
Wang, Jianhua
author_facet Zhao, Fei
Yang, Na
Wang, Xiumin
Mao, Ruoyu
Hao, Ya
Li, Zhanzhan
Wang, Xiao
Teng, Da
Fan, Huan
Wang, Jianhua
author_sort Zhao, Fei
collection PubMed
description Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on multidrug resistant S. suis was studied for the first time. MP1102 exhibited significant antibacterial activity against S. suis (minimum inhibitory concentration, MIC = 0.028–0.228 μM), rapid bacteriocidal action, a longer postantibiotic effect than ceftriaxone, and a synergistic or additive effect with lincomycin, penicillin, and ceftriaxone (FICI = 0.29–0.96). No resistant mutants appeared after 30 serial passages of S. suis in the presence of MP1102. Flow cytometric analysis and electron microscopy observations showed that MP1102 destroyed S. suis cell membrane integrity and affected S. suis cell ultrastructure and membrane morphology. Specifically, a significantly wrinkled surface, intracellular content leakage, and cell lysis were noted, establishing a cyto-basis of nonresistance to this pathogen. DNA gel retardation and circular dichroism analysis indicated that MP1102 interacted with DNA by binding to DNA and changing the DNA conformation, even leading to the disappearance of the helical structure. This result further supported the mechanistic basis of nonresistance via interaction with an intracellular target, which could serve as a means of secondary injury after MP1102 is transported across the membrane. Upon treatment with 2.5–5.0 mg/kg MP1102, the survival of mice challenged with S. suis was 83.3–100%. MP1102 decreased bacterial translocation in liver, lung, spleen, and blood; inhibited the release of interleukin-1β and tumor necrosis factor-α; and relieved the lung, liver, and spleen from acute injury induced by S. suis. These results suggest that MP1102 is a potent novel antibacterial agent for the treatment of porcine streptococcal disease.
format Online
Article
Text
id pubmed-6399382
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63993822019-03-12 In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 Zhao, Fei Yang, Na Wang, Xiumin Mao, Ruoyu Hao, Ya Li, Zhanzhan Wang, Xiao Teng, Da Fan, Huan Wang, Jianhua Front Cell Infect Microbiol Cellular and Infection Microbiology Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on multidrug resistant S. suis was studied for the first time. MP1102 exhibited significant antibacterial activity against S. suis (minimum inhibitory concentration, MIC = 0.028–0.228 μM), rapid bacteriocidal action, a longer postantibiotic effect than ceftriaxone, and a synergistic or additive effect with lincomycin, penicillin, and ceftriaxone (FICI = 0.29–0.96). No resistant mutants appeared after 30 serial passages of S. suis in the presence of MP1102. Flow cytometric analysis and electron microscopy observations showed that MP1102 destroyed S. suis cell membrane integrity and affected S. suis cell ultrastructure and membrane morphology. Specifically, a significantly wrinkled surface, intracellular content leakage, and cell lysis were noted, establishing a cyto-basis of nonresistance to this pathogen. DNA gel retardation and circular dichroism analysis indicated that MP1102 interacted with DNA by binding to DNA and changing the DNA conformation, even leading to the disappearance of the helical structure. This result further supported the mechanistic basis of nonresistance via interaction with an intracellular target, which could serve as a means of secondary injury after MP1102 is transported across the membrane. Upon treatment with 2.5–5.0 mg/kg MP1102, the survival of mice challenged with S. suis was 83.3–100%. MP1102 decreased bacterial translocation in liver, lung, spleen, and blood; inhibited the release of interleukin-1β and tumor necrosis factor-α; and relieved the lung, liver, and spleen from acute injury induced by S. suis. These results suggest that MP1102 is a potent novel antibacterial agent for the treatment of porcine streptococcal disease. Frontiers Media S.A. 2019-02-26 /pmc/articles/PMC6399382/ /pubmed/30863725 http://dx.doi.org/10.3389/fcimb.2019.00048 Text en Copyright © 2019 Zhao, Yang, Wang, Mao, Hao, Li, Wang, Teng, Fan and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Zhao, Fei
Yang, Na
Wang, Xiumin
Mao, Ruoyu
Hao, Ya
Li, Zhanzhan
Wang, Xiao
Teng, Da
Fan, Huan
Wang, Jianhua
In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title_full In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title_fullStr In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title_full_unstemmed In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title_short In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
title_sort in vitro/vivo mechanism of action of mp1102 with low/nonresistance against streptococcus suis type 2 strain cvcc 3928
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399382/
https://www.ncbi.nlm.nih.gov/pubmed/30863725
http://dx.doi.org/10.3389/fcimb.2019.00048
work_keys_str_mv AT zhaofei invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT yangna invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT wangxiumin invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT maoruoyu invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT haoya invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT lizhanzhan invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT wangxiao invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT tengda invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT fanhuan invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928
AT wangjianhua invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928